said Monday that it submitted a new drug application to the Food and Drug Administration for its Parkinson's disease treatment rasagiline.
The application is based on the results from three Phase III clinical trials involving patients with early and advanced Parkinson's disease, Teva said.
Earlier this month, the company said that rasagiline added to levodopa therapy reduced the total time when Parkinson's symptoms aren't adequately controlled by 1.2 hours daily, or 21%.
Teva also said Monday that it expects to submit an application to market rasagiline as a treatment for Parkinson's in the European Union later this year.
Shares of Teva were up 50 cents, or 0.8%, in afternoon trading to $60.18.